Nuformix Advances Inhaled Lung Treatment, NXP002
Company Announcements

Nuformix Advances Inhaled Lung Treatment, NXP002

Nuformix Plc (GB:NFX) has released an update.

Nuformix Plc, a pharmaceutical company specializing in drug repurposing for fibrosis and oncology, reports a reduced half-year loss before tax and continues progress on its inhaled treatment for fibrotic lung diseases, NXP002. The company has secured patents in Japan and Europe for NXP002 and received milestone payments from the sale of its NXP001 patent estate. With a lean operational model, Nuformix remains focused on generating data and securing partnerships for their novel drug candidates.

For further insights into GB:NFX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskNuformix Directors Boost Stake in Fundraising Effort
TipRanks UK Auto-Generated NewsdeskNuformix Approves New Shares, Eyes Growth in Market
TipRanks UK Auto-Generated NewsdeskNuformix Announces Major Fundraising and Share Issuance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App